X-376
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206616

CAS#: 1365267-27-1

Description: X-376 is an ALK inhibitor and potentially useful in non-small cell lung cancer.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 750
1g
USD 2450
Size
Price

25mg
USD 330
200mg
USD 1250
2g
USD 3950
Size
Price

50mg
USD 550
500mg
USD 1850
5g
USD 6450

X-376, purity > 98%, is in stock. The same day shipping after order received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 206616
Name: X-376
CAS#: 1365267-27-1
Chemical Formula: C25H25Cl2FN6O3
Exact Mass: 546.1349
Molecular Weight: 547.4124
Elemental Analysis: C, 54.85; H, 4.60; Cl, 12.95; F, 3.47; N, 15.35; O, 8.77


Related CAS #: 1370651-20-9   1365267-27-1    

Synonym: X-376; X 376; X376

IUPAC/Chemical Name: 6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-3-pyridazinecarboxamide

InChi Key: ONPGOSVDVDPBCY-CQSZACIVSA-N

InChi Code: InChI=1S/C25H25Cl2FN6O3/c1-14(21-17(26)7-8-18(28)22(21)27)37-20-13-19(31-32-23(20)29)24(35)30-16-5-3-15(4-6-16)25(36)34-11-9-33(2)10-12-34/h3-8,13-14H,9-12H2,1-2H3,(H2,29,32)(H,30,35)/t14-/m1/s1

SMILES Code: O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4CCN(C)CC4)=O)C=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47. doi: 10.1177/1758834015617355. Review. PubMed PMID: 26753004; PubMed Central PMCID: PMC4699265.

2: Qiu W, Yuchi M, Ding M, Tessier D, Fenster A. Needle segmentation using 3D Hough transform in 3D TRUS guided prostate transperineal therapy. Med Phys. 2013 Apr;40(4):042902. doi: 10.1118/1.4795337. PubMed PMID: 23556924.

3: Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31. doi: 10.1158/0008-5472.CAN-10-3879. Epub 2011 May 25. PubMed PMID: 21613408; PubMed Central PMCID: PMC3138877.

4: Byrne PV. Human myeloid cells possessing high-affinity receptors for granulocyte-macrophage colony stimulating factor. Leuk Res. 1989;13(2):117-26. PubMed PMID: 2538682.